0.3637
Schlusskurs vom Vortag:
$0.3593
Offen:
$0.36
24-Stunden-Volumen:
978.20K
Relative Volume:
0.36
Marktkapitalisierung:
$45.33M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.2425
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
+11.53%
1M Leistung:
-0.60%
6M Leistung:
-31.05%
1J Leistung:
-81.81%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRSN
Mersana Therapeutics Inc
|
0.3637 | 40.64M | 36.86M | -171.67M | -171.05M | -1.50 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-06 | Eingeleitet | William Blair | Outperform |
2024-11-15 | Fortgesetzt | Citigroup | Buy |
2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-07-27 | Herabstufung | Truist | Buy → Hold |
2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-06-15 | Eingeleitet | Guggenheim | Buy |
2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-01-20 | Eingeleitet | Citigroup | Buy |
2022-11-21 | Eingeleitet | Truist | Buy |
2021-10-15 | Fortgesetzt | BTIG Research | Buy |
2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
2020-12-03 | Eingeleitet | Stifel | Buy |
2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
2020-04-29 | Eingeleitet | BTIG Research | Buy |
2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
What drives Mersana Therapeutics Inc. stock priceHigh-octane financial growth - jammulinksnews.com
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Group Entry - Newser
Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior return velocity - jammulinksnews.com
Is Mersana Therapeutics Inc. a good long term investmentExponential return rates - jammulinksnews.com
What analysts say about Mersana Therapeutics Inc. stockHigh-impact investment strategies - jammulinksnews.com
Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
What makes Mersana Therapeutics Inc. stock price move sharplyTop Performing Low Risk Stocks - Newser
How Mersana Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
Wealth Enhancement Advisory Services LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Mersana Therapeutics Settles Debt with Oxford Finance - TipRanks
Biotech layoff tracker: 18 companies cut 1,300 jobs in Q2 2025 - The Business Journals
Mersana Therapeutics (MRSN) Plunges 5.23% Amid Drug Trial Data - AInvest
94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World
Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World
Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World
Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa
Mersana reports promising Phase 1 ADC trial results - Investing.com India
Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus
Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq
Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):